Selective induction of p38 mitogen-activated protein kinase activity following A6H co-stimulation in primary human CD4(+) T cells. NLM AIDSLINE Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Selective induction of p38 mitogen-activated protein kinase activity following A6H co-stimulation in primary human CD4(+) T cells.

Int Immunol. 2000 Mar;12(3):253-61. Unique Identifier : AIDSLINE MED/20166977
Labuda T; Sundstedt A; Dohlsten M; BMC Immunobiology, Department of Tumor Immunology, University of; Lund, Solvegatan 21, 223 62 Lund, Sweden.


Abstract: We have recently described the novel A6H antigen expressed on human peripheral blood T cells and on renal cell carcinoma cells. Cross-linking of the A6H antigen results in co-stimulation of human CD4(+) T cells, characterized by induction of the transcription factor activator protein-1 (AP-1), proliferation and prominent IFN-gamma production, but low levels of IL-2. The proximal signaling events associated with A6H ligation include protein tyrosine kinase phosphorylation and association of p56 Lck, ZAP-70 and the TCR zeta chain. In this study we show that A6H co-stimulation selectively induced activation of the p38 mitogen-activated protein kinase (MAPK) pathway, whereas no significant c-Jun N-terminal kinases (JNK) activity was observed. In contrast, CD28 co-stimulation resulted in both p38 and JNK MAPK activities. Human CD4(+) T cells co-stimulated with A6H up-regulated AP-1 binding proteins reactive with a proximal AP-1 binding site in the human IFN-gamma promoter and a consensus AP-1 binding site. Moreover, preincubation of the T cells with the specific p38 MAPK inhibitor SB203580 resulted in decreased AP-1 binding following A6H or CD28 co-stimulation. This suggests that the p38 MAPK pathway is required for induction of full AP-1 binding activity in human CD4(+) T cells co-stimulated with A6H or CD28. Blocking the p38 MAPK pathway by SB203580 completely inhibited IFN-gamma production from A6H co-stimulated T cells and radically reduced IFN-gamma production from T cells co-stimulated with anti-CD28. In contrast, no significant inhibition of IL-2 production was seen after blocking of the p38 MAPK in either A6H or CD28 co-stimulated T cells. Since the p38 MAPK recently has been shown to be critically involved in regulation of IFN-gamma production from T(h)1 cells, we propose that A6H co-stimulation induces a specific pathway, mediated via p38 and AP-1 activation, for induction of a T(h)1 profile in human CD4(+) T cells.


Keywords: JOURNAL ARTICLE Antigens, CD28/IMMUNOLOGY Antigens, Neoplasm/*IMMUNOLOGY Binding Sites Ca(2+)-Calmodulin Dependent Protein Kinase/ANTAGONISTS & INHIB/ *BIOSYNTHESIS/GENETICS Cell Division Cells, Cultured Consensus Sequence CD4-Positive T-Lymphocytes/*ENZYMOLOGY Enzyme Induction Enzyme Inhibitors/PHARMACOLOGY Gene Expression Regulation Human Imidazoles/PHARMACOLOGY Interferon Type II/BIOSYNTHESIS/GENETICS *Lymphocyte Transformation Mitogen-Activated Protein Kinases/METABOLISM Muromonab-CD3/PHARMACOLOGY *MAP Kinase Signaling System Promoter Regions (Genetics) Pyridines/PHARMACOLOGY Support, Non-U.S. Gov't Th1 Cells/*CYTOLOGY/METABOLISM Transcription Factor AP-1/METABOLISM Transcription, GeneticKWDjournalarticleantigens,cd28/immunologyantigens,neoplasm/KWDimmunologybindingsitesca(2+)-calmodulindependentproteinkinase/antagonists&inhib/KWDbiosynthesis/geneticscelldivisioncells,culturedconsensussequencecd4-positivet-lymphocytes/KWDenzymologyenzymeinductionenzymeinhibitors/pharmacologygeneexpressionregulationhumanimidazoles/pharmacologyinterferontypeii/biosynthesis/geneticsKWDlymphocytetransformationmitogen-activatedproteinkinases/metabolismmuromonab-cd3/pharmacologyKWDmapkinasesignalingsystempromoterregions(genetics)pyridines/pharmacologysupport,non-uKWDsKWDgov'tth1cells/KWDcytology/metabolismtranscriptionfactorap-1/metabolismtranscription,genetic
000730
A0071483

Copyright © 2000 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .